

REMARKS

This paper is filed to correct an inadvertent misstatement made in the amendment filed March 27, 2008.

At page 7, paragraphs 3, 4 and 5, in the previous amendment, the following comments were made.

In another instance Example 2 shows that a commercially available LMWP (Sanofi Recherche, Gentilly Codex, France, described in paragraph 0176) was able to neutralize anticoagulant function of heparin (paragraph 0178) and induce less complement activation than full length protamine (paragraph 0180).

Thus, the specification teaches not only preparation of LMWP recited in the claimed methods, but also where such LMWP can be commercially obtained.

Combining these disclosures with the fact that full-length protamine is known in the art and its amino acid sequence understood (see for example, the instant office action at the paragraph bridging pages 6 and 7 wherein the examiner sets forth common knowledge in the art, as well as paragraphs 0103 through 0110 in the published application), it must be concluded that the specification expressly contemplates methods of inactivating heparin with protamine fragments having low level immunogenicity (compared to full length protamine) as recited in the rejected claims.

The statement that Example 2 discloses a commercially available low molecular weight *protamine* (LMWP) is incorrect in that Example 2 actually discloses commercial availability of a low molecular weight *heparin* (LMWH). This misstatement was made without deceptive intent and correction of the error does not affect the substance of the argument against the rejection.

The fact remains that the application unambiguously teaches preparation of LMWP and that this LMWP is able to neutralize heparin and induce a lower level of complement activation. Regardless of whether LMWP was commercially available, the applicants reiterate that the Written Description Guidelines admits that an applicant can show possession of the claimed invention by describing distinguishing, identifying characteristics sufficient to show that the applicant was in possession of the claimed invention (See 66 FR 1104, col. 3.), and that in the case of the presently claimed *methods*, the distinguishing characteristic is not

the structural characteristics of LMWP compounds *per se*, but rather the steps of the inactivating heparin using a protamine fragment having a specific molecular weight. See 66 FR 1106, cols. 1-2, distinguishing structures of products from steps of a process. Examples 1 and 2 make is unambiguously clear that the applicants were in possession of such a method using LMWP.

CONCLUSION

The applicants respectfully request that this correction be made of record and submit again that, in view of the amendments and remarks made herein and previously made of record, all claims are believed to be in condition for allowance and respectfully request notification of the same.

Dated: April 23, 2008

Respectfully submitted,

By 
Joseph A. Williams, Jr.

Registration No.: 38,659

MARSHALL, GERSTEIN & BORUN LLP
233 S. Wacker Drive, Suite 6300
Sears Tower
Chicago, Illinois 60606-6357
(312) 474-6300
Attorney for Applicant